title: Managing hot flashes in men being treated for prostate cancer.
abstract: Prostate cancer is the most common malignancy in men. Treatment with hormonal ablation is often accompanied by disabling hot flashes. This article reviews the pathophysiology of hot flashes and treatment options for this common side effect of treatment.
authors.affiliation: Tulane Medical School, New Orleans, USA.
authors.forename: Neil H
authors.initials: NH
authors.lastname: Baum
authors.forename: Dorothea C
authors.initials: DC
authors.lastname: Torti
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003131:Combined Modality Therapy; D000529:Complementary Therapies; D003511:Cyclohexanols / Q000627:therapeutic use; D004054:Diethylstilbestrol / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000627:therapeutic use; D019584:Hot Flashes / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D008297:Male; D019290:Megestrol Acetate / Q000627:therapeutic use; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D013739:Testosterone / Q000097:blood; D000069470:Venlafaxine Hydrochloride
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D003511:Cyclohexanols; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D004054:Diethylstilbestrol; D000069470:Venlafaxine Hydrochloride; D019290:Megestrol Acetate